Concepedia

Publication | Closed Access

A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.

97

Citations

101

References

2002

Year

Carol J. Fabian, Bruce F. Kimler, Deborah A Brady, Matthew S. Mayo, Chih‐Hsiang Chang, John A. Ferraro, Carola M. Zalles, Annette L. Stanton, Shahla Masood, William E. Grizzle,
PubMed

Abstract

DFMO at a dose level of 0.5 g/m(2)/day administered for 6 months does not modulate breast risk biomarkers tested in this study.

References

YearCitations

Page 1